Gilead Sciences Inc. (GILD)

$121.10 (Stock Price as of 01/09/2026)

Price Target (6-12 Months): **$132.00**

Long Term: 6-12 Months	**Zacks Recommendation:** (Since: 05/31/24) Prior Recommendation: Underperform	**Neutral**
Short Term: 1-3 Months	**Zacks Rank:** (1-5)	**3-Hold**
	Zacks Style Scores:	VGM: B
	Value: B | Growth: B | Momentum: D	

Summary

Gilead's HIV growth driver Biktarvy maintained its dominant position despite the Medicare Part D redesign in 2015. The company now expects HIV sales to grow approximately 5% in 2025 from its prior assumption of 3%. Our sales estimates for Biktarvy indicate a CAGR of around 5.5% over the next three years. The recent FDA approval of lenacapavir under the brand name Yeztugo further solidifies its HIV portfolio. Lenacapavir has also received approval in the EU. Gilead is also developing additional HIV treatments which if approved should strengthen the HIV franchise in the wake of increasing competition. Gilead's efforts to bolster its oncology and virology franchises through collaborations are impressive.

Price, Consensus & Surprise(1)

Data Overview

52 Week High-Low	**$128.68 - $88.57**
20 Day Average Volume (sh)	**5,763,888**
Market Cap	**$150.2 B**
YTD Price Change	**-1.3%**
Beta	**0.33**
Dividend / Div Yld	**$3.16 / 2.6%**
Industry	**Medical - Biomedical and Genetics**
Zacks Industry Rank	**Top 37% (91 out of 244)**
Last EPS Surprise	**14.9%**
Last Sales Surprise	**4.2%**
EPS F1 Est- 4 week change	**0.1%**
Expected Report Date	**02/10/2026**
Earnings ESP	**-2.8%**
P/E TTM	**14.8**
P/E F1	**15.0**
PEG F1	**0.5**
P/S TTM	**5.2**

Sales and EPS Growth Rates (Y/Y %)(2)



Sales Estimates (millions of $)(2)

	Q1	Q2	Q3	Q4	Annual*
2026	6,909 E	7,264 E	7,716 E	7,768 E	29,657 E
2025	6,667 A	7,082 A	7,769 A	7,542 E	29,060 E
2024	6,686 A	6,954 A	7,545 A	7,569 A	28,754 A

EPS Estimates(2)

	Q1	Q2	Q3	Q4	Annual*
2026	1.69 E	1.80 E	2.34 E	2.32 E	8.16 E
2025	1.81 A	2.01 A	2.47 A	1.81 E	8.10 E
2024	-1.32 A	2.01 A	2.02 A	1.90 A	4.62 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 01/09/2026.
(2) The report's text, the analyst-provided estimates, and the price target are as of 12/30/2025.

Overview

Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV). The company's broad portfolio includes drugs for liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. Gilead has a strong HIV franchise with flagship treatment Biktarvy driving the growth. The company's efforts to develop innovative HIV treatments for prevention are impressive as well. Total sales from the HIV franchise were $19.6 billion in 2024, up 8% year over year, driven by strong growth in lead HIV treatment Biktarvy.

As of 12/30/2025

Gilead's liver disease portfolio includes chronic hepatitis C virus (HCV) drugs, chronic hepatitis B virus drugs Vemlidy and Viread, and other chronic hepatitis delta virus (HDV) products. For 2024, the liver disease portfolio generated sales of $3 billion, up 9% year over year.

Gilead is also looking to build an oncology franchise to diversify its virology portfolio. Yescarta, the first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted accelerated approval in the United States in July for the treatment of relapsed or refractory mantle cell lymphoma. The Cell Therapy Product franchise delivered a stellar performance in 2024 with sales of $2 billion, which rose 6% year over year.

Gilead is making inroads in the oncology space with strategic collaborations and acquisitions. It acquired oncology company Immunomedics for approximately $21 billion in 2020, which added the breast cancer drug Trodelvy to its portfolio. Trodelvy, for breast cancer, solidifies its oncology franchise and provides a strong opportunity for growth. Trodelvy's sales surged 24% to $1.3 billion in 2024, reflecting strong demand in new and existing geographies.

Gilead has a robust late-stage pipeline that bodes well for long-term growth. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Veklury (remdesivir), for the treatment of COVID-19 patients, generated sales of $1.8 billion in 2024, down 18% year over year. This was due to lower rates of COVID-19-related hospitalizations.

Total revenues in 2024 were $28.8 billion, up 6% from the 2023 level.

As of 01/09/2026

Reasons To Buy:

> Gilead's strong HIV franchise and the growing oncology franchise should drive growth for the company.

- **Strong HIV Franchise**: Gilead is a dominant player in the HIV market. The company was the first to bring a single-tablet regimen (STR) to the market for the treatment of HIV and grabbed a formidable market share.

  The HIV franchise received a significant boost when the FDA approved its once-daily STR, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection. Biktarvy has become the number-one prescribed regimen for both treatment-naïve and switch patients. It continues to maintain its dominant position with an increasing market share for treatment and prevention. Biktarvy accounts for more than 52% share of the treatment market in the United States and should maintain momentum.

  Gilead had earlier announced settlement agreements to resolve Biktarvy patent litigation with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd.

- Per the terms of the settlement, the earliest date the three generic manufacturers can market a generic version of full dose Biktarvy in the United States is April 1, 2036, subject to standard acceleration provisions. GILD had earlier projected Biktarvy to lose exclusivity in December 2033.

  Descovy accounts for more than 45% of the U.S. market share in pre-exposure prophylaxis (PrEP) market. The FDA recently approved lenacapavir for the prevention of HIV under the brand name Yeztugo for PrEP to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35 kg. The FDA nod, granted under Priority Review, was based on extraordinary data from the late-stage studies, PURPOSE 1 and PURPOSE 2 studies, which showed that ?99.9% of participants who received Yeztugo remained HIV-negative.

  As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers that have limited broader PrEP adoption, such as challenges with daily oral PrEP, adherence, stigma and healthcare access. This approval represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice yearly, unlike daily oral pills, which address a broad population. The approval significantly boosts Gilead's HIV franchise, as lenacapavir needs to be taken twice yearly, unlike daily oral pills. Gilead's shares have outperformed the industry over the past year.

  Gilead now expects HIV revenue growth in 2025 to be approximately 5% (previous guidance: 3%), despite a $900 million headwind for this business due to the Medicare Part D redesign. Our estimates for Biktarvy suggest a CAGR of around 5.5% over the next three years, driven by continued market growth.

  Gilead also initiated a phase III PURPOSE-365 evaluating once yearly lenacapavir for PrEP. The company is also developing seven combination regimens that utilize lenacapavir-based molecules for HIV treatment. With the approval of Yeztugo, GILD is targeting up to eight additional HIV product launches before the end of 2033, including five that would come to market by the end of 2030.

- **Diversification Into the Oncology Space**: Gilead is looking to expand beyond antivirals into the lucrative oncology market. To that end, Gilead's acquisition of an oncology company added Trodelvy (sacituzumabgovitecan-hziy), a first-in-class antibody-drug conjugate, to its portfolio. The addition of Trodelvy has accelerated the company's efforts to develop a strong and diverse oncology portfolio and reduce dependence on its virology business. The drug is approved as a third-line treatment for metastatic triple-negative breast cancer. The uptake of the drug is impressive and Gilead's efforts to expand the drug's label should yield positive results. The drug was also approved to treat pre-treated HR+/HER2- metastatic breast cancer and has already become the leading regimen in second-line metastatic triple-negative breast cancer across both the United States and Europe. Additional label expansion of the drug (in first-line metastatic triple negative breast cancer) will further boost its sales.

  Our estimates for Trodelvy indicate a CAGR of around 12.5% over the next three years.

  Gilead had earlier acquired Kite Pharma to foray into the emerging field of cell therapy. Kite's Yescarta is approved for treating refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma and primary mediastinal B-cell lymphoma. Yescarta is also approved for the treatment of adult patients with LBCL who are refractory to first-line chemoimmunotherapy or relapse within 12 months of receiving first-line chemoimmunotherapy. The continued uptake of Yescarta in DLBCL, notably in the United States, continues to drive growth for Yescarta.

  The FDA approval of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) has strengthened its cell therapy franchise. Tecartus approval for the treatment of relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia in patients aged 26 and above has expanded this franchise.

  Gilead and partner Arcellx are also evaluating anitocabtagene-autoleucel in R/R multiple myeloma. Updates are expected later this year.

- **Efforts to Strengthen Liver Disease Portfolio**: The Liver Disease portfolio includes treatments for HCV, chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV). Gilead is making efforts to develop this franchise with new treatments like Hepcludex, which recently received full marketing authorization in the European Union for the treatment of adults with chronic HDV and compensated liver disease. Incremental sales from this franchise will boost the top line.

  The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in

adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA, has strengthened the liver disease portfolio. The candidate was approved under the brand name Livdelzi. Seladelpar was added to Gilead's portfolio/pipeline through the acquisition of CymaBay Therapeutics Inc. for $4.3 billion in March 2024. Livdelzi enjoys Orphan Drug Designation for the treatment of PBC patients in the United States. It was also granted Breakthrough Therapy Designation by the FDA. The drug was also approved in the EU. Livdelzi put up a stellar performance year to date on the back of strong commercial execution and some new launches outside the country.

- **Collaborations and Deals to Develop Pipeline**: Gilead has advanced strategic alliances to advance its pipeline, saving time and resources involved in developing a drug from scratch. Kite entered into a strategic partnership with Arcellx to co-develop and co-commercialize CART-ddBMCA, a late-stage clinical asset in development for the treatment of multiple myeloma (MM). This partnership was recently expanded to develop CART-ddBCMA to treat lymphomas. Kite also exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in MM indication. Gilead has also partnered with Arcus to evaluate the combinations of domvanalimab plus zimberelimab (doublet) and domvanalimab plus zimberelimab and etrumadenant (triplet) versus zimberelimab monotherapy in patients with first-line, metastatic PD-L1-high non-small cell lung cancer. Gilead entered into a 12-year partnership with Assembly Biosciences to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, HBV and HDV.

  Gilead Sciences has a research collaboration, option and license agreement with Merus to discover novel dual tumor-associated antigens targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus' proprietary Triclonics platform, along with Gilead's oncology expertise, to research and develop multiple, separate preclinical research programs.

Reasons To Sell:

> Dependence on the HIV franchise is concerning. Pipeline setbacks and stiff competition remain threats as well.

- **Competition in the HIV Business**: Competition for the core HIV franchise from the likes of GSK and Janssen Pharmaceuticals might limit additional market share gains. The loss of exclusivity of Atripla and Truvada has adversely impacted sales. Total revenues in 2025 are likely to be adversely impacted due to the new Medicare Part D model.

- **Potential Challenges for Trodelvy**: While Trodelvy is doing well, competition in the breast cancer market is a headwind. The late-stage study evaluating Trodelvy in previously treated metastatic non-small cell lung cancer failed, denting Gilead's efforts to expand the drug's label in this lucrative space.

- **Cell Therapy Franchise Under Pressure**: The Cell Therapy franchise, comprising Yescarta and Tecartus, is under pressure due to competitive headwinds.

- **Pipeline Setbacks**: Gilead is no stranger to pipeline setbacks. It suffered a setback when Trodelvy did not meet the primary endpoint of improvement in overall survival (OS) in the intention-to-treat population of the confirmatory late-stage TROPiCS-04 study in locally advanced or metastatic urothelial cancer. Earlier, EVOKE-01, evaluating Trodelvy in patients with metastatic or advanced non-small cell lung cancer, did not meet its primary endpoint of OS.

  The late-stage ASCENT-07 study investigating Trodelvy versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2- negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival as assessed by Blinded Independent Central Review ("BICR") according to RECIST v1.1 criteria.

- **Unfavorable Debt Profile**: As of Sept. 30, 2025, Gilead's total debt-to-total-capital ratio was 0.54, which compares unfavorably with 0.42 for its peer group. A higher ratio indicates higher financial risk and vice versa. While the company's cash balance of $9.4 billion is strong, a high debt level is concerning.

Last Earnings Report

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow

FY Quarter Ending	12/31/2025
Earnings Reporting Date	**Oct 30, 2025**
Sales Surprise	**4.16%**
EPS Surprise	**14.88%**
Quarterly EPS	**2.47**
Annual EPS (TTM)	**8.19**

Gilead posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales guidance. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus Estimate of $2.15 and were up from $2.02 a year ago.

Total revenues of $7.8 billion also beat the Zacks Consensus Estimate of $7.5 billion. Revenues were up 3% year over year, driven by higher HIV and Livdelzi (seladelpar) sales.

However, the stock was down in after-market trading on Oct. 30. The stock was also down in pre-market trading on Oct. 31. This can be attributed to a decline in total product sales.

GILD's Q3 Highlights

Total revenues comprise product sales and royalty, contract and other revenues.

While revenues increased year over year, driven by higher royalty, contract and other revenues, product sales were down 2% to $7.3 billion due to lower Veklury (remdesivir) and Cell Therapy sales.

Excluding Veklury, product sales increased 4% to $7.1 billion.

HIV product sales grew 4% year over year to $5.3 billion, primarily driven by increased demand and favorable inventory dynamics. The figure beat both the Zacks Consensus Estimate and our model estimate of $5.2 billion.

Flagship HIV therapy Biktarvy's sales increased 6% year over year to $3.7 billion, driven by higher demand and favorable inventory dynamics. The reported number beat both the Zacks Consensus Estimate of $3.6 billion and our model estimate of $3.65 billion.

Per GILD, Biktarvy accounts for over 52% share of the treatment market in the United States, and continues to be the market leader in major markets around the world.

Descovy (FTC 200 mg/TAF 25 mg) sales increased 20% year over year to $701 million, driven by higher demand. The reported number beat the Zacks Consensus Estimate of $629 million and our model estimate of $633 million. Descovy accounts for more than 45% of the U.S. market share in pre-exposure prophylaxis (PrEP).

The newly approved Yeztugo (lenacapavir) for PrEP raked in sales of $39 million in the third quarter.

The Liver Disease portfolio sales, which include chronic HCV, chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV), increased 12% to $819 million, primarily driven by higher demand for Livdelzi for the treatment of primary biliary cholangitis (PBC).

Veklury sales plunged 60% to $277 million, primarily due to lower rates of COVID-19-related hospitalizations. Sales missed the Zacks Consensus Estimate of $344 million and our model estimate of $368 million.

Cell Therapy product (comprising Yescarta and Tecartus) sales decreased 11% to $432 million due to competitive headwinds. The figure missed the Zacks Consensus Estimate of $476 million and our model estimate of $461 million.

Yescarta sales decreased 10% year over year to $349 million due to lower demand. Tecartus (adult acute lymphoblastic leukemia) sales decreased 15% to $83 million due to lower demand.

Breast cancer drug Trodelvy's sales increased 7% year over year to $357 million, driven by higher demand. Trodelvy's sales missed the Zacks Consensus Estimate of $369 million but matched our model estimate.

GILD's Cost Analysis

Adjusted product gross margin was relatively flat year over year at 86.5%.

Research and development expenses totaled $1.3 billion, down from $1.4 billion in the year-ago quarter due to lower study-related and clinical manufacturing expenses.

SG&A expenses amounted to $1.4 billion, flat year over year as lower corporate expenses were largely offset by higher HIV promotional expenses.

Acquired IPR&D expenses totaled $170 million in the reported quarter, primarily reflecting an upfront payment of $120 million related to Gilead's collaboration with Shenzhen Pregene Biopharma Co., Ltd.

During the third quarter of 2025, Gilead paid dividends of $1.0 billion and repurchased $435 million of common stock.

As of Sept. 30, 2025, Gilead had $9.4 billion in cash, cash equivalents and marketable debt securities compared with $7.1 billion as of Jun. 30, 2025.

GILD Updates 2025 Guidance

Gilead now expects product sales to be between $28.4 billion and $28.7 billion (previous guidance: $28.3-$28.7 billion). The Zacks Consensus Estimate for 2025 revenues is pinned at $28.8 billion.

Total product sales, excluding Veklury, are expected between $27.4 billion and $27.7 billion (previous guidance: $27.3-$27.7 billion). Total Veklury sales are still estimated to be $1 billion.

Adjusted EPS is now anticipated to be in the range of $8.05-$8.25 (previous guidance: $7.95-$8.25). The Zacks Consensus Estimate for 2025 EPS is pegged at $8.07.

Key Pipeline and Regulatory Updates From GILD

GILD announced settlement agreements to resolve Biktarvy patent litigation with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd.

Per the terms of the settlement, the earliest date the three generic manufacturers can market a generic version of full dose Biktarvy in the United States is April 1, 2036, subject to standard acceleration provisions.

GILD had earlier projected Biktarvy to lose exclusivity in December 2033.

GILD obtained marketing authorization for Yeytuo (lenacapavir) in the EU for use as PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk.

GILD also announced the acquisition of Interius BioTherapeutics, Inc., a privately held biotechnology company developing in vivo therapeutics, for $350 million.

The acquisition complements Kite's cell therapy expertise by integrating Interius's in vivo platform.

The company has also filed for FDA approval of bulevirtide for the treatment of chronic hepatitis delta virus.

Recent News

Exercises Option to License Assembly Biosciences' Programs – Dec. 22

Gilead recently announced that it has exercised its combined option to exclusively license Assembly Biosciences' herpes simplex virus (HSV) helicase-primase inhibitor programs. The HSV programs include novel long-acting investigational candidates, ABI-1179 and ABI-5366, which are being developed in early-stage studies for recurrent genital herpes.

This marks the first programs that Gilead will advance under its ongoing collaboration with Assembly Bio.

Gilead entered into a 12-year partnership with Assembly Biosciences to advance the research and development of novel antiviral therapies in 2023.

Per the agreement, Assembly Bio will receive a payment of $35 million following Gilead's exercise of its option for the combined HSV program, which includes ABI-5366 and ABI-1179. Gilead will obtain an exclusive license to ABI-5366 and ABI-1179 and assume full responsibility for their clinical development and commercialization.

ASMB will be eligible to receive up to $330 million in regulatory and commercial milestones, along with tiered royalties on net sales.

Agreement With the Government – Dec. 19

Gilead announced an agreement with the government to reduce drug costs for Americans.

The company will provide discounts on certain existing medicines within the U.S. Medicaid program, similar to what is paid in comparably developed nations, including select medications to treat HIV, Hepatitis C, Hepatitis B and COVID-19.

The terms of the agreement are confidential. Gilead also recently announced that it will invest $32 billion in U.S.-based manufacturing, R&D, and infrastructure over the next five years. This investment is projected to generate $43 billion in national economic value and create more than 3,000 direct and indirect jobs.

Investigational HIV Treatment Meets Goal – Dec. 15

Gilead announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the treatment of HIV met the primary endpoint in the late-stage ARTISTRY-2 study.

ARTISTRY-2 is a multicenter, double-blind, randomized phase III study comparing the safety and efficacy of an investigational once-daily combination of bictegravir and lenacapavir (BIC/LEN) versus Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in people with HIV who are virologically suppressed.

Participants receiving Biktarvy were randomized in a 2:1 ratio to either switch to bictegravir 75 mg/lenacapavir 50 mg or continue on their existing regimen.

The primary endpoint was the proportion of patients with HIV-1 RNA ?50 copies/mL at week 48 as determined by the FDA-defined snapshot algorithm.

Data showed BIC/LEN efficacy was found to be statistically non-inferior to Biktarvy.

Data on Yescarta – Dec. 7

Gilead presented a new analysis today demonstrating that second-line Yescarta (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those who are ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).

Results were shared from the combined analysis of four-year data from the landmark ZUMA-7 Phase 3 pivotal study of Yescarta for R/R LBCL and two-year data from the phase II ALYCANTE study, designed by French collaborative group LYSA and sponsored by LYSARC, for transplant-ineligible patients.

Investigational Regimen for HIV Treatment Meets Primary Goal – Nov. 13

Gilead announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study.

This study is a multicenter phase II/III study comparing the investigational once-daily combination of bictegravir, a global guidelines-recommended integrase strand transfer inhibitor, and lenacapavir, a first-in-class capsid inhibitor, versus current therapy in HIV patients who are virologically suppressed on complex regimens.

Participants in the ARTISTRY-1 study were randomized in the ratio of 2:1 to receive a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg or continue their stable baseline complex regimen.

Results from the ARTISTRY-1 study showed that the once-daily STR of bictegravir and lenacapavir met the primary success criterion for non-inferiority to baseline multi-tablet antiretroviral therapy regimens. The primary efficacy endpoint was the percentage of participants with HIV-1 RNA levels ?50 copies/mL at week 48, defined by the FDA snapshot algorithm.

Results showed that combination was generally well tolerated, with no significant or new safety concerns identified.

Gilead plans to file the late-stage data from the ARTISTRY trials with regulatory authorities.

Update on ASCENT-07 Study – Nov 7

Gilead announced the phase III ASCENT-07 study investigating Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria.

Overall survival, a key secondary endpoint, was not mature at the time of the primary analysis. Nonetheless, an early trend was observed favoring patients treated with Trodelvy compared to chemotherapy. The ASCENT-07 study will continue to further assess overall survival.

Data on Trodelvy – Oct. 19

Gilead shared positive data from the phase III ASCENT-03 study, which demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors.

Valuation

Gilead's shares are up 10.6% in the past six months and up 33.7% over the trailing 12-month period. Stocks in the Zacks sub-industry and the sector are up 26.7% and up 12.8%, respectively in the past six months. Over the past year, Zacks sub-industry and sector are up 20.2% and 7.8%, respectively. The S&P 500 Index is up 14.1% in the past six months and up 19.8% in the past year.

The stock is currently trading at 14.7X forward 12-month earnings per share which compares 38.18X for the Zacks sub-Industry, 21.21X for the Zacks sector and 23.35X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 21.16X and as low as 8.45X, with a 5-year median of 10.96X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our $132 price target reflects 15.5X forward 12-month earnings per share.

The table below shows summary valuation data for GILD

Valuation Multiples - GILD

		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	14.7	38.18	21.21	23.35
	5-Year High	21.16	55.58	23.59	23.8
	5-Year Low	8.45	23.82	17.84	15.74
	5-Year Median	10.96	36.59	20.62	21.23
P/S F12M	Current	5.15	1.92	2.16	5.29
	5-Year High	5.32	3.48	3.41	5.49
	5-Year Low	2.84	1.65	2.03	3.82
	5-Year Median	3.57	2.26	2.65	5.04
P/B TTM	Current	7.22	3.65	4.07	8.57
	5-Year High	7.65	5.93	6.1	9.13
	5-Year Low	3.45	2.92	3.59	6.57
	5-Year Median	4.59	3.66	4.54	8.04

As of 12/29/2025 *Source: Zacks Investment Research*

Industry Analysis(1)

Zacks Industry Rank: Top 37% (91 out of 244)

Top Peers (1)

Company (Ticker)	Rec	Rank
Regeneron Pharmaceut…**(REGN)**	Outperform	1
Amgen Inc. **(AMGN)**	Neutral	3
Biogen Inc. **(BIIB)**	Neutral	4
Bristol Myers Squibb…**(BMY)**	Neutral	3
CSL Limited Sponsore…**(CSLLY)**	Neutral	3
GSK PLC Sponsored AD…**(GSK)**	Neutral	3
Moderna, Inc. **(MRNA)**	Neutral	3
Vertex Pharmaceutica…**(VRTX)**	Neutral	3

Industry Comparison(1)

Industry: Medical - Biomedical And Genetics | Industry Peers

	GILD	X Industry	S&P 500	AMGN	CSLLY	GSK
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	3
VGM Score	A	-	-	B	D	A
Market Cap	150.25 B	160.10 M	40.82 B	175.60 B	56.79 B	102.72 B
# of Analysts	11	3	22	14	1	5
Dividend Yield	2.61%	0.00%	1.37%	2.92%	2.60%	3.38%
Value Score	B	-	-	B	C	A
Cash/Price	0.05	0.31	0.04	0.05	0.04	0.05
EV/EBITDA	37.22	-1.62	15.04	16.37	12.59	13.81
PEG Ratio	0.45	1.56	2.08	2.97	2.04	1.26
Price/Book (P/B)	7.00	2.90	3.46	18.26	2.65	4.82
Price/Cash Flow (P/CF)	17.63	17.69	15.58	10.74	13.38	9.03
P/E (F1)	14.95	21.50	18.90	15.06	17.58	10.31
Price/Sales (P/S)	5.17	6.87	3.12	4.88	NA	2.44
Earnings Yield	7.05%	-16.42%	5.28%	6.64%	5.69%	9.70%
Debt/Equity	1.03	0.00	0.57	5.45	0.50	0.95
Cash Flow ($/share)	6.87	-1.45	8.98	30.37	4.37	5.58
Growth Score	B	-	-	C	C	B
Hist. EPS Growth (3-5 yrs)	-5.67%	4.20%	8.24%	5.77%	NA	3.08%
Proj. EPS Growth (F1/F0)	75.32%	12.10%	9.21%	7.21%	0.00%	12.10%
Curr. Cash Flow Growth	-23.19%	-4.07%	7.00%	15.75%	10.17%	8.40%
Hist. Cash Flow Growth (3-5 yrs)	-1.50%	4.07%	7.49%	7.76%	10.93%	1.36%
Current Ratio	1.45	4.29	1.19	1.28	2.46	0.84
Debt/Capital	50.78%	0.00%	38.14%	84.50%	33.31%	48.60%
Net Margin	27.88%	-116.58%	12.77%	19.47%	NA	17.16%
Return on Equity	51.86%	-65.79%	17.03%	162.59%	NA	48.64%
Sales/Assets	0.51	0.32	0.53	0.40	NA	0.54
Proj. Sales Growth (F1/F0)	1.10%	14.60%	5.30%	8.80%	4.60%	7.00%
Momentum Score	B	-	-	B	F	A
Daily Price Chg	0.36%	0.00%	0.65%	-1.21%	-0.43%	0.34%
1 Week Price Chg	-2.49%	-1.74%	1.76%	-1.59%	-1.36%	1.12%
4 Week Price Chg	-1.71%	-1.67%	0.95%	2.75%	-2.53%	3.09%
12 Week Price Chg	2.76%	-3.59%	5.09%	10.24%	-18.35%	15.12%
52 Week Price Chg	35.85%	-7.63%	17.71%	23.42%	-34.66%	49.30%
20 Day Average Volume	5,763,888	334,252	2,445,854	2,547,822	137,716	3,006,007
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.66%
(F1) EPS Est 4 week change	0.14%	0.00%	0.00%	0.11%	-4.03%	0.62%
(F1) EPS Est 12 week change	0.40%	1.31%	0.47%	1.15%	-6.59%	2.56%
(Q1) EPS Est Mthly Chg	5.33%	0.00%	0.00%	-1.23%	NA	0.00%

Analyst Earnings Model[2]

Gilead Sciences, Inc. (GILD)

In $MM, except per share data

FY Ends December 31st	2022A FY Dec-22	2023A FY Dec-23	2024A FY Dec-24	2025E 1QA 31-Mar-25	2025E 2QA 30-Jun-25	2025E 3QA 30-Sep-25	2025E 4QE 31-Dec-25	2025E FY Dec-25	2026E 1QE 31-Mar-26	2026E 2QE 30-Jun-26	2026E 3QE 30-Sep-26	2026E 4QE 31-Dec-26	2026E FY Dec-26	2027E FY Dec-27
Income Statement														
Product Sales	$26,982.0	$26,934.0	$28,610.0	$6,613.0	$7,054.0	$7,345.0	$7,497.0	$28,509.0	$6,833.7	$7,199.7	$7,621.3	$7,720.8	$29,375.5	$31,470.5
Royalty, Contract & Other Revenues	$299.0	$182.0	$144.0	$54.0	$27.0	$424.0	$45.5	$550.5	$75.0	$64.5	$94.2	$47.5	$281.2	$336.7
Total Revenue	**$27,281.0**	**$27,116.0**	**$28,754.0**	**$6,667.0**	**$7,082.0**	**$7,769.0**	**$7,542.4**	**$29,060.4**	**$6,908.7**	**$7,264.2**	**$7,715.5**	**$7,768.3**	**$29,656.7**	**$31,807.2**
COGS, Non-GAAP	$3,602.0	$3,697.0	$3,936.0	$961.0	$922.0	$992.0	$1,068.8	$3,943.8	$1,052.3	$1,003.5	$1,026.8	$1,066.4	$4,149.0	$4,454.1
COGS, GAAP	$5,657.0	$6,498.0	$6,251.0	$1,540.0	$1,501.0	$1,569.0	$1,653.4	$6,263.4	$1,574.4	$1,579.9	$1,626.8	$1,869.2	$6,650.3	$6,971.9
Gross Profit, Non-GAAP	**$23,679.0**	**$23,420.0**	**$24,818.0**	**$5,706.0**	**$6,160.0**	**$6,777.0**	**$6,473.6**	**$25,116.6**	**$5,856.4**	**$6,260.7**	**$6,688.7**	**$6,701.9**	**$25,507.6**	**$27,353.1**
Gross Profit, GAAP	**$21,624.0**	**$20,619.0**	**$22,503.0**	**$5,127.0**	**$5,581.0**	**$6,200.0**	**$5,889.0**	**$22,797.0**	**$5,334.3**	**$5,684.2**	**$6,088.8**	**$5,899.1**	**$23,006.4**	**$24,835.2**
Selling, General & Administrative, Non-GAAP	$5,587.0	$6,060.0	$5,903.0	$1,222.0	$1,358.0	$1,351.0	$1,436.9	$5,367.9	$1,484.2	$1,540.2	$1,399.6	$1,397.4	$5,821.3	$6,129.2
Selling, General & Administrative, GAAP	$5,673.0	$6,090.0	$6,091.0	$1,258.0	$1,365.0	$1,357.0	$1,443.6	$5,423.6	$1,490.0	$1,588.3	$1,417.3	$1,422.2	$5,917.8	$6,191.6
Research & Development, Non-GAAP	$4,968.0	$5,720.0	$5,732.0	$1,338.0	$1,450.0	$1,334.0	$1,581.4	$5,703.4	$1,522.4	$1,683.8	$1,442.7	$1,506.3	$6,155.2	$6,400.4
Research & Development, GAAP	$4,977.0	$5,718.0	$5,907.0	$1,379.0	$1,491.0	$1,346.0	$1,591.9	$5,807.9	$1,614.3	$1,714.4	$1,452.5	$1,558.2	$6,339.4	$6,570.8
In-Process Research & Development Impairment	$2,700.0	$50.0	$4,180.0	$0.0	$190.0	$0.0	$0.0	$190.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Acquired In-Process Research & Development Expenses	$944.0	$1,155.0	$4,663.0	$253.0	$61.0	$170.0	$415.0	$899.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Costs & Expenses, Non-GAAP	**$15,102.0**	**$16,634.0**	**$20,234.0**	**$3,774.0**	**$3,791.0**	**$3,847.0**	**$4,502.1**	**$15,914.1**	**$4,058.8**	**$4,227.5**	**$3,869.1**	**$3,970.1**	**$16,125.5**	**$16,983.7**
Total Costs & Expenses, GAAP	**$19,951.0**	**$19,511.0**	**$27,092.0**	**$4,430.0**	**$4,608.0**	**$4,442.0**	**$5,104.0**	**$18,584.0**	**$4,678.7**	**$4,882.7**	**$4,496.6**	**$4,849.5**	**$18,907.5**	**$19,734.4**
Depreciation	$323.0	$354.0	$381.0	$97.0	$93.0	$90.0	$93.3	$373.3	$100.0	$96.4	$93.2	$96.5	$386.1	$418.1
Amortization	$1,780.0	$2,339.0	$2,386.0	$599.0	$598.0	$596.0	$596.0	$2,389.0	$596.0	$596.0	$596.0	$596.0	$2,384.0	$2,384.0
Operating Income, Non-GAAP	**$12,180.0**	**$10,484.0**	**$8,520.0**	**$2,893.0**	**$3,290.0**	**$3,921.0**	**$3,040.3**	**$13,144.3**	**$2,849.9**	**$3,036.7**	**$3,846.4**	**$3,798.2**	**$13,531.2**	**$14,823.5**
Operating Income, GAAP	**$7,330.0**	**$7,605.0**	**$1,662.0**	**$2,237.0**	**$2,474.0**	**$3,327.0**	**$2,438.4**	**$10,476.4**	**$2,230.0**	**$2,381.5**	**$3,218.9**	**$2,918.7**	**$10,749.2**	**$12,072.8**
Interest Expense	$935.0	$944.0	$977.0	$260.0	$254.0	$256.0	$241.1	$1,011.1	$260.7	$253.8	$250.5	$259.3	$1,024.3	$1,096.8
Other (Income)/ Expenses Net, Non-GAAP	($77.0)	($365.0)	($279.0)	($98.0)	($66.0)	($87.0)	($84.7)	($335.7)	($99.4)	($65.9)	($80.2)	($98.0)	($343.5)	($349.0)
Other (Income)/ Expenses Net, GAAP	$581.0	($198.0)	($6.0)	$328.0	($208.0)	($569.0)	($13.4)	($462.4)	$145.0	($3.3)	($266.4)	($99.3)	($223.9)	($233.8)
Pre-Tax Income, Non-GAAP	**$11,320.0**	**$9,904.0**	**$7,823.0**	**$2,731.0**	**$3,102.0**	**$3,752.0**	**$2,883.9**	**$12,468.9**	**$2,688.6**	**$2,848.8**	**$3,676.1**	**$3,636.9**	**$12,850.4**	**$14,075.7**
Pre-Tax Income, GAAP	**$5,814.0**	**$6,859.0**	**$690.0**	**$1,649.0**	**$2,429.0**	**$3,641.0**	**$2,210.7**	**$9,929.7**	**$1,824.3**	**$2,131.0**	**$3,234.8**	**$2,758.7**	**$9,948.8**	**$11,209.8**
Income Tax, Non-GAAP	$2,184.8	$1,505.4	$2,026.2	$445.2	$583.2	$656.6	$628.7	$2,313.6	$586.1	$621.0	$801.4	$792.8	$2,801.4	$3,068.5
Income Tax, GAAP	$1,248.0	$1,247.0	$211.0	$334.0	$468.0	$589.0	$196.8	$1,587.8	$162.4	$447.5	$679.3	$579.3	$1,868.5	$2,354.1
Tax Rate, Non-GAAP	19.3%	15.2%	25.9%	16.3%	18.8%	17.5%	21.8%	18.6%	21.8%	21.8%	21.8%	21.8%	21.8%	21.8%
Tax Rate, GAAP	21.5%	18.2%	30.5%	20.2%	19.3%	16.2%	8.9%	16.0%	8.9%	21.0%	21.0%	21.0%	18.8%	21.0%
Net Income/ (Loss)	**$4,566.0**	**$5,613.0**	**$480.0**	**$1,315.0**	**$1,960.0**	**$3,052.0**	**$2,014.0**	**$8,341.0**	**$1,661.9**	**$1,683.5**	**$2,555.5**	**$2,179.4**	**$8,080.3**	**$8,855.7**
Non-Controlling Interests	$26.0	$52.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Net Income/ (Loss) Attributable to Gilead, Non-GAAP	**$9,158.0**	**$8,454.0**	**$5,795.0**	**$2,285.0**	**$2,521.0**	**$3,095.0**	**$2,255.2**	**$10,156.2**	**$2,102.5**	**$2,227.8**	**$2,874.7**	**$2,844.1**	**$10,049.0**	**$11,007.2**
Net Income/ (Loss) Attributable to Gilead, GAAP	**$4,592.0**	**$5,665.0**	**$480.0**	**$1,315.0**	**$1,960.0**	**$3,052.0**	**$2,014.0**	**$8,341.0**	**$1,661.9**	**$1,683.5**	**$2,555.5**	**$2,179.4**	**$8,080.3**	**$8,855.7**
Basic Shares Outstanding	1,255.0	1,248.0	1,247.0	1,246.0	1,245.0	1,243.0	1,237.0	1,242.8	1,231.0	1,225.0	1,219.0	1,213.0	1,222.0	1,198.0
Diluted Shares Outstanding, Non-GAAP	1,262.0	1,258.0	1,255.0	1,259.0	1,255.0	1,254.0	1,248.0	1,254.0	1,242.0	1,236.0	1,230.0	1,224.0	1,233.0	1,209.0
Diluted Shares Outstanding, GAAP	1,262.0	1,258.0	1,255.0	1,259.0	1,255.0	1,254.0	1,248.0	1,254.0	1,242.0	1,236.0	1,230.0	1,224.0	1,233.0	1,209.0
Basic EPS	**$3.66**	**$4.54**	**$0.38**	**$1.06**	**$1.57**	**$2.46**	**$1.63**	**$6.72**	**$1.35**	**$1.37**	**$2.10**	**$1.80**	**$6.62**	**$7.40**
Diluted EPS, Non-GAAP	**$7.26**	**$6.72**	**$4.62**	**$1.81**	**$2.01**	**$2.47**	**$1.81**	**$8.10**	**$1.69**	**$1.80**	**$2.34**	**$2.32**	**$8.16**	**$9.11**
Diluted EPS, GAAP	**$3.64**	**$4.50**	**$0.38**	**$1.04**	**$1.56**	**$2.43**	**$1.61**	**$6.64**	**$1.34**	**$1.36**	**$2.08**	**$1.78**	**$6.56**	**$7.33**
Dividend per Share	$2.92	$3.00	$3.08	$0.79	$0.79	$0.79	$0.79	$3.16	$0.81	$0.81	$0.81	$0.81	$3.24	$3.32
Dividends	$3,709.0	$3,709.0	$3,918.0	$1,010.0	$994.0	$1,005.0	$985.9	$3,994.9	$1,006.0	$1,001.2	$996.3	$991.4	$3,994.9	$4,013.9

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	B
Momentum Score	D
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.